+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Musculoskeletal System Disorder Drug Market - Global Forecast 2026-2032- Product Image
Musculoskeletal System Disorder Drug Market - Global Forecast 2026-2032- Product Image
New

Musculoskeletal System Disorder Drug Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 195 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6123770
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The musculoskeletal system disorder drug market is experiencing an evolution in therapeutic approaches and stakeholder expectations. Market growth is being driven by rising chronic disease prevalence, aging populations, and an increasing need for function-focused, value-driven treatments in complex clinical scenarios.

Market Snapshot: Musculoskeletal System Disorder Drug Market

The musculoskeletal system disorder drug market is projected to increase from USD 91.83 billion in 2025 to USD 95.69 billion in 2026, continuing at a compound annual growth rate of 4.56% to reach USD 125.48 billion by 2032. This trajectory reflects ongoing demand for therapies that address chronic pain, disability, and the long-term impacts of musculoskeletal diseases, with stakeholders requiring evidence of functional outcomes and real-world value.

Scope & Segmentation

This report comprehensively covers the musculoskeletal system disorder drug market across core segments and regions, integrating clinical, regulatory, and commercial perspectives.

  • Disorder Types: Osteoarthritis, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, psoriatic arthritis, gout, and other degenerative, autoimmune, and metabolic conditions
  • Drug Classes: Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, DMARDs (conventional and advanced), biologics, targeted synthetic therapies, and urate-lowering agents
  • Route of Administration: Oral, injectable (self-administered and intravenous), and emerging at-home administration technologies
  • Distribution Channels: Specialty pharmacies, hospital pharmacies, retail pharmacies, and online pharmacies
  • End Users: Hospitals, specialty clinics, homecare settings, and integrated digital health providers
  • Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific, with particular attention to payer architecture and biosimilar maturity
  • Technological Innovations: Auto-injectors, real-world evidence platforms, digital adherence tools, cold-chain solutions, and biomarker-informed treatment approaches

Key Takeaways

  • Therapeutic strategies are increasingly tailored to diverse patient profiles, requiring alignment with heterogeneity in disease biology, comorbidities, and care preferences.
  • Clinical and commercial success now depend on demonstrating real-world durability, function, and patient engagement, not just efficacy in controlled environments.
  • Device design, service quality, and channel convenience have become competitive differentiators as patients and payers prioritize ease of use and consistent access.
  • Biosimilar and generic competition is shifting focus from price alone to switching confidence, immunogenicity, and value-added services especially with self-injectables.
  • Regional market performance is influenced by regulatory sophistication, adoption of specialty infrastructure, and variable access driven by local reimbursement policies.

Tariff Impact: Shaping Supply Chain and Net Cost-to-Serve

Recent US tariffs are affecting supply chain resilience, particularly for complex inputs such as APIs, packaging, devices, and temperature-controlled logistics. Manufacturers are mapping exposure, increasing dual sourcing, and rebalancing procurement to sustain uninterrupted therapy delivery. Tariffs heighten payer cost scrutiny and intensify contracting negotiations, especially where multiple therapeutic alternatives exist. As companies localize manufacturing and adapt to evolving trade policies, resilience is prioritized alongside cost management in market strategies.

Methodology & Data Sources

The research utilizes a structured approach combining systematic secondary data from regulatory documents, clinical literature, and health system publications with primary stakeholder interviews. Expert feedback from clinicians, payers, and supply chain leaders validates insights and clarifies key adoption drivers, barriers, and segmentation trends. Data triangulation is applied to ensure robust, actionable conclusions reflecting real-world decision criteria.

Why This Report Matters

  • Enables strategic leaders to identify resilient growth opportunities by mapping clinical, operational, and regulatory shifts impacting musculoskeletal drug markets.
  • Supports commercial and supply chain teams in adapting to tariff risks and evolving regional access models with targeted insights for decision-making.
  • Guides product, market access, and medical affairs functions to strengthen value demonstrations for payers, providers, and patients in complex care pathways.

Conclusion

Stakeholders in the musculoskeletal system disorder drug market face rising expectations for long-term outcomes and cost predictability. Those who combine lifecycle execution, robust evidence, and patient-centric solutions will be best positioned for sustained advancement in dynamic regional environments.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Musculoskeletal System Disorder Drug Market, by Drug Class
8.1. Biologics
8.2. Corticosteroids
8.3. Disease Modifying Antirheumatic Drugs
8.4. Nonsteroidal Anti-Inflammatory Drugs
9. Musculoskeletal System Disorder Drug Market, by Indication
9.1. Ankylosing Spondylitis
9.2. Osteoarthritis
9.3. Psoriatic Arthritis
9.4. Rheumatoid Arthritis
10. Musculoskeletal System Disorder Drug Market, by Route Of Administration
10.1. Injectable
10.1.1. Intravenous
10.1.2. Subcutaneous
10.2. Oral
10.2.1. Capsule
10.2.2. Tablet
10.3. Topical
10.3.1. Cream
10.3.2. Gel
11. Musculoskeletal System Disorder Drug Market, by Dosage Form
11.1. Capsule
11.2. Gel
11.3. Injectable
11.3.1. Intravenous
11.3.2. Subcutaneous
11.4. Tablet
12. Musculoskeletal System Disorder Drug Market, by Distribution Channel
12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies
13. Musculoskeletal System Disorder Drug Market, by End User
13.1. Ambulatory Surgery Centers
13.2. Clinics
13.3. Homecare Settings
13.4. Hospitals
14. Musculoskeletal System Disorder Drug Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Musculoskeletal System Disorder Drug Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Musculoskeletal System Disorder Drug Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Musculoskeletal System Disorder Drug Market
18. China Musculoskeletal System Disorder Drug Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AbbVie Inc.
19.6. Amgen Inc.
19.7. Astellas Pharma
19.8. AstraZeneca plc
19.9. Bayer AG
19.10. Biogen Inc.
19.11. Bristol-Myers Squibb Company
19.12. Celgene Corporation
19.13. Daiichi Sankyo Company, Ltd.
19.14. Eli Lilly and Company
19.15. Gilead Sciences, Inc.
19.16. GlaxoSmithKline plc
19.17. Horizon Therapeutics plc
19.18. Johnson & Johnson
19.19. Merck & Co., Inc.
19.20. Novartis AG
19.21. Pfizer Inc.
19.22. Regeneron Pharmaceuticals, Inc.
19.23. Roche Holding AG
19.24. Sanofi S.A.
19.25. Sun Pharmaceutical Industries Ltd.
19.26. Takeda Pharmaceutical Company Limited
19.27. Teva Pharmaceutical Industries Ltd.
19.28. UCB S.A.
19.29. Viatris
List of Figures
FIGURE 1. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 149. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 150. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 152. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 153. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 154. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 155. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 156. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 157. EUROPE MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 171. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 172. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 173. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 174. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 175. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 176. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 177. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 178. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. AFRICA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 192. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 194. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 195. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 196. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 197. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 198. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 199. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 200. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 201. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 202. ASEAN MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 205. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 206. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 208. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 209. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 210. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 211. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 212. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 213. GCC MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 226. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 227. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 228. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 230. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 231. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 232. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 233. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 234. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 235. BRICS MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 237. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 238. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 239. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 240. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 241. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 242. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 243. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 244. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 245. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 246. G7 MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 247. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 248. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 249. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 250. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 251. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 252. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 253. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 254. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 255. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 256. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 257. NATO MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 258. GLOBAL MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 264. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 267. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 269. UNITED STATES MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 270. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 271. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 272. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 273. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 274. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 275. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 276. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
TABLE 277. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 278. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 279. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 280. CHINA MUSCULOSKELETAL SYSTEM DISORDER DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Musculoskeletal System Disorder Drug market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company, Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Horizon Therapeutics plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Viatris

Table Information

Report AttributeDetails
No. of Pages195
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 95.69 Billion
Forecasted Market Value ( USD ) by 2032 $ 125.48 Billion
Compound Annual Growth Rate4.5%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Musculoskeletal System Disorder Therapeutics Market - Global Forecast 2026-2032 - Product Image

Musculoskeletal System Disorder Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Generic Musculoskeletal Disorders Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Generic Musculoskeletal Disorders Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Generic Musculoskeletal Disorders Drugs Market Report 2025 - Product Image

Generic Musculoskeletal Disorders Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Diclofenac Market Report and Forecast 2025-2034 - Product Image

Diclofenac Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Musculoskeletal Drugs Market - Global Strategic Business Report - Product Image

Musculoskeletal Drugs Market - Global Strategic Business Report

  • Report
  • 286 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.